Показати простий запис статті
dc.contributor.author |
Chekhun, V.F. |
|
dc.contributor.author |
Zhylchuk, V.E. |
|
dc.contributor.author |
Lukyanova, N.Yu. |
|
dc.contributor.author |
Vorontsova, A.L. |
|
dc.contributor.author |
Kudryavets, Yu.I. |
|
dc.date.accessioned |
2018-06-15T14:21:07Z |
|
dc.date.available |
2018-06-15T14:21:07Z |
|
dc.date.issued |
2009 |
|
dc.identifier.citation |
Expression of drug resistance proteins in triple-receptor-negative tumors as the basis of individualized therapy of the breast cancer patients / V.F. Chekhun, V.E. Zhylchuk, N.Yu. Lukyanova, A.L. Vorontsova, Yu.I. Kudryavets // Experimental Oncology. — 2009. — Т. 31, № 2. — С. 123–124. — назв. — англ. |
uk_UA |
dc.identifier.issn |
1812-9269 |
|
dc.identifier.uri |
http://dspace.nbuv.gov.ua/handle/123456789/135725 |
|
dc.description.abstract |
Aim: To evaluate the efficacy ofthe application of various chemotherapy schemes based on the immunohistochemical study of expression
patterns of proteins associated with the drug resistance P-glycoprotein (P-gp), glutathione-S-transferase (GST), metallothioneins
(МТ) of breast cancer (BC) patients with the triple-receptor-negative (RE–, RP–, HER-2/neu–) cancer. Methods and Results: P-gp,
GST and МТ expression in BC-biopsy samples from 60 BC patients was evaluated by immunohistochemical analysis. The results
of the clinical observations showed that 3-years relapse-free survival rate of the patients of with P-gp, GST and МТ-positive tumors
treated with taxoter + adriablastin / taxoter + cyclophosphamide (ТА/ТС), gemcitabine + carboplatin, or TC + bevacizumab was
61.5%, 78.6% and 81.2% respectively, vs 41.2% in the control group with P-gp, GST and МТ-negative tumors treated with adriablastin
+ cyclophosphamide (p < 0.05), while overall survival rates were 84.4%, 92.6% and 93.8% respectively vs 70.6% in the control
group (p < 0.05). Conclusion: The study points on the possibility to elevate the efficiency of polychemotherapy by its individualization
based on the expression patterns of Р-gp, GST and MT on tumor cells of the patients with the triple-receptor-negative BC. |
uk_UA |
dc.language.iso |
en |
uk_UA |
dc.publisher |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України |
uk_UA |
dc.relation.ispartof |
Experimental Oncology |
|
dc.subject |
Short communications |
uk_UA |
dc.title |
Expression of drug resistance proteins in triple-receptor-negative tumors as the basis of individualized therapy of the breast cancer patients |
uk_UA |
dc.type |
Article |
uk_UA |
dc.status |
published earlier |
uk_UA |
Файли у цій статті
Ця стаття з'являється у наступних колекціях
Показати простий запис статті